• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Coherus BioSciences Inc.

    4/16/25 5:37:54 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CHRS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Coherus BioSciences, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    19249H103

    (CUSIP Number)


    04/14/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    19249H103


    1Names of Reporting Persons

    Thomas A. Satterfield, Jr.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    585,000.00
    6Shared Voting Power

    5,424,514.00
    7Sole Dispositive Power

    585,000.00
    8Shared Dispositive Power

    5,424,514.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,009,514.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  * Based on 115,896,849 shares of common stock of the issuer outstanding as of February 28, 2025, as reported by the issuer on its Annual Report on Form 10-K for the year ended December 31, 2024.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Coherus BioSciences, Inc.
    (b)Address of issuer's principal executive offices:

    333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065
    Item 2. 
    (a)Name of person filing:

    Thomas A. Satterfield, Jr.
    (b)Address or principal business office or, if none, residence:

    15 Colley Cove Drive Gulf Breeze, FL 32561
    (c)Citizenship:

    Incorporated by reference from Item 4 of the Cover Page.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    19249H103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Incorporated by reference from Item 9 of the Cover Page.
    (b)Percent of class:

    Incorporated by reference from Item 11 of the Cover Page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Incorporated by reference from Item 5 of the Cover Page.

     (ii) Shared power to vote or to direct the vote:

    Incorporated by reference from Item 6 of the Cover Page.

     (iii) Sole power to dispose or to direct the disposition of:

    Incorporated by reference from Item 7 of the Cover Page.

     (iv) Shared power to dispose or to direct the disposition of:

    Incorporated by reference from Item 8 of the Cover Page.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 100,000 shares are held jointly with Rebecca S. Satterfield, Mr. Satterfield's spouse; 750,000 shares are held by Tomsat Investment & Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 2,200,000 shares are held by Caldwell Mill Opportunity Fund, which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager; and 1,612,514 shares are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield. Additionally, Mr. Satterfield has limited powers of attorney for voting and disposition purposes with respect to the following shares: Thomas A. Satterfield, Sr. (200,000 shares); Rebecca S. Satterfield (65,000); Parker Satterfield (32,000 shares); Jeanette Satterfield Kaiser (155,000 shares); Richard W. Kaiser (65,000 shares); Rita Phifer (70,000 shares); Parker Little Trust (10,000 shares); Lola Little Trust (10,000 shares); Henry Beck (30,000 shares); John and Angela Picton (50,000); Christy Beard (7,000); Paula and Gene Colley (25,000); Glenna and Jesse Colley (35,000); Alex Flannery (4,000); and Camile Richards (4,000). These individuals and entities have the right to receive or the power to direct the receipt of the proceeds from the sale of their respective shares.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Thomas A. Satterfield, Jr.
     
    Signature:/s/ Thomas A. Satterfield, Jr.
    Name/Title:Thomas A. Satterfield, Jr.
    Date:04/16/2025
    Get the next $CHRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHRS

    DatePrice TargetRatingAnalyst
    8/16/2024$4.00 → $1.50Buy → Neutral
    UBS
    11/17/2023$11.00Outperform
    Robert W. Baird
    11/8/2023Buy → Hold
    Maxim Group
    7/24/2023$12.00Buy
    Citigroup
    5/1/2023$24.00Buy
    Truist
    3/28/2023$11.00Neutral → Buy
    UBS
    6/14/2022$7.00Neutral
    UBS
    3/7/2022$15.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $CHRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

      REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, May 12, 2025, starting at 5:00 p.m. Eastern Daylight Time To access the conference call, please pre-register through

      5/5/25 4:01:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus to Participate in Upcoming Investor Conferences

      REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that the company will be webcasting its participation in the upcoming conferences: Citizens Life Science Conference in New York, NY on Thursday, May 8, 2025 at 9:00 a.m. Eastern Daylight Time / 6:00 a.m. Pacific Daylight Time – Webcast LinkHCW BioConnect @ Nasdaq NYC 2025 in New York, NY on Tuesday, May 20, 2025 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time – Webcast LinkTD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA taking place virtually on Tuesday, May 27, 2025 at 3:00 p.m. Eastern Daylight Time / 12:00 p.m. Pacific D

      5/1/25 5:04:28 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

      – CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time– REDWOOD CITY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced data from its ongoing Phase 1

      4/28/25 10:10:11 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Leadership Updates

    Live Leadership Updates

    See more
    • Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

      REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility. As Global Controller at Merck, Ms. Karachun managed a global team responsible for all accou

      6/5/24 9:00:00 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

       – Recognized biopharma commercialization and market access leader to support Coherus' strategic vision and multiple product launches – REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced the appointment to its Board of Directors of biopharma commercialization and market access expert Michael Ryan, Pharm. D. Dr. Ryan has four decades of experience working in academia and the biopharmaceutical industry bringing high-value therapeutics to patients. Dr. Ryan's distinguished career includes most recently serving as Senior Vice President and Head for U.S. and Worldwide Value, Access, Pricing and Health Ec

      7/20/23 4:04:53 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of Directors

      - Dr. O'Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute's efforts to advance cancer immunotherapies - REDWOOD CITY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (("Coherus", NASDAQ:CHRS) today announced the appointment of cancer immunotherapy leader Jill O'Donnell-Tormey, Ph.D., to its Board of Directors. Dr. O'Donnell-Tormey will also serve on the Nominating and Corporate Governance Committee of the Board of Directors. Dr. O'Donnell-Tormey is the Chief Executive Officer and Director of Scientific Affairs of the Cancer Research Institute ("CRI"), a nonprofit organization dedicated exclusively to

      5/11/22 6:00:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Mcmichael Bryan J

      4 - Coherus BioSciences, Inc. (0001512762) (Issuer)

      5/9/25 5:59:16 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President & CEO Lanfear Dennis M

      4 - Coherus BioSciences, Inc. (0001512762) (Issuer)

      5/9/25 5:58:02 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Mcmichael Bryan J covered exercise/tax liability with 1,711 shares, decreasing direct ownership by 7% to 22,951 units (SEC Form 4)

      4 - Coherus BioSciences, Inc. (0001512762) (Issuer)

      1/22/25 7:51:11 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Financials

    Live finance-specific insights

    See more
    • Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

      REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Monday, May 12, 2025, starting at 5:00 p.m. Eastern Daylight Time To access the conference call, please pre-register through

      5/5/25 4:01:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

      – CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time– REDWOOD CITY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS), today announced data from its ongoing Phase 1

      4/28/25 10:10:11 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

      REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced that its fourth quarter and full year 2024 financial results will be released after market close on Monday, March 10, 2025. Starting at 5:00 p.m. ET on March 10, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. Conference Call Information When: Monday, March 10, 2025, starting at 5:00 p.m. Eastern Time To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.me

      3/3/25 8:30:00 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Coherus BioSciences Inc.

      DEFA14A - Coherus BioSciences, Inc. (0001512762) (Filer)

      4/29/25 4:07:12 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Coherus BioSciences Inc.

      DEF 14A - Coherus BioSciences, Inc. (0001512762) (Filer)

      4/29/25 4:05:21 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences Inc. filed SEC Form 8-K: Leadership Update

      8-K - Coherus BioSciences, Inc. (0001512762) (Filer)

      4/25/25 4:05:22 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Coherus BioSciences Inc.

      SC 13G - Coherus BioSciences, Inc. (0001512762) (Subject)

      11/13/24 4:30:25 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Coherus BioSciences Inc.

      SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)

      7/23/24 8:23:56 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Coherus BioSciences Inc. (Amendment)

      SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)

      5/22/24 7:27:00 PM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Coherus BioSciences downgraded by UBS with a new price target

      UBS downgraded Coherus BioSciences from Buy to Neutral and set a new price target of $1.50 from $4.00 previously

      8/16/24 7:33:26 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Coherus BioSciences with a new price target

      Robert W. Baird initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $11.00

      11/17/23 7:37:50 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus BioSciences downgraded by Maxim Group

      Maxim Group downgraded Coherus BioSciences from Buy to Hold

      11/8/23 9:19:04 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CHRS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

      Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

      5/22/24 9:41:01 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

      Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

      4/23/24 4:41:07 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

      Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

      12/27/23 4:38:39 AM ET
      $CHRS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care